← Eichor
Study identifier: NCT06923397 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Condition: Lymphoma · Lymphoma, Hodgkin · Lymphoma, Non-Hodgkin  ·  Sponsor: Dana-Farber Cancer Institute

PhaseNA
Planned participants24
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.

This description comes directly from the study's public registry record.

Talk to the study team

Christina Dieli-Conwright, MD, PhD  ·  617-582-8321  ·  ChristinaM_Dieli-Conwright@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Dana Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06923397